Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis

Ther Drug Monit. 2024 Oct 1;46(5):611-618. doi: 10.1097/FTD.0000000000001198. Epub 2024 Apr 4.

Abstract

Background: Posaconazole is a vital drug to treat and prevent invasive fungal infections. Several factors, such as sex, body weight, total serum proteins, dietary intake, and severe mucositis, affect posaconazole pharmacokinetics (PKs). However, the relevance of other factors that affect the PKs of posaconazole in hematopoietic stem cell transplantation (HSCT) is unknown. This study explored factors influencing the PKs of posaconazole in HSCT recipients and nontransplant patients with hematological diseases.

Methods: The authors conducted a single-institution, retrospective study. Forty-two Japanese inpatients receiving oral posaconazole tablets as prophylaxis for fungal infections were enrolled in this study. A one-compartment model with first-order absorption was used as the structural pharmacokinetic model. A population PK (PopPK) analysis was performed using a nonlinear mixed-effects modeling program, using a first-order conditional estimation method with interactions. Perl-speaks-NONMEM and R were used to evaluate the goodness of fit and visualize the output.

Results: In 29% of the enrolled patients, the serum concentration of posaconazole was <0.5 mcg/mL, considered the effective range. PopPK analysis revealed that the patient had undergone HSCT within 1 year, diarrhea occurred more than 5 times a day, and aspartate aminotransferase were covariates that influenced apparent clearance (CL/F). The CL/F of posaconazole was 1.43-fold higher after HSCT and 1.26-fold higher during diarrhea.

Conclusions: PopPK analysis revealed that HSCT, diarrhea, and aspartate aminotransferase were factors associated with the CL/F of posaconazole. The trough concentration of posaconazole may be below the therapeutic range in a few patients with diarrhea and/or after HSCT. As invasive fungal infections in patients with hematologic diseases can be life-threatening, therapeutic drug monitoring of posaconazole is strongly recommended, and patients should be carefully monitored.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Antifungal Agents* / pharmacokinetics
  • Antifungal Agents* / therapeutic use
  • East Asian People
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Models, Biological*
  • Mycoses* / prevention & control
  • Retrospective Studies
  • Triazoles* / pharmacokinetics
  • Triazoles* / therapeutic use
  • Young Adult

Substances

  • Antifungal Agents
  • posaconazole
  • Triazoles